Medical News / ESC 2022 - SGLT2 Inhibitor Therapy Foundational in Wide Range of Heart Failure Management

SGLT2 inhibitors reduce the risk of hospitalization for heart failure, extend survival, and improve overall health status, irrespective of ejection fraction, in patients with heart failure. Source: MDMag To view the third party content, kindly click on the link below or read more. You will then leave this site and enter a third party site.

read more

New research into the speed of diagnosis of hypertrophic cardiomyopathy in the United States is providing ... read more
In a recent study, a smartphone app using artificial intelligence (AI) predicted heart failure 3 weeks ... read more
Reducing sodium in diet to 4,000 mg/day significantly lowers blood pressure after 1 week, a new ... read more
On November 12, 2023, Lexicon Pharmaceuticals, Inc. announced a post hoc analysis of clinical data from ... read more